| Filed On | Filing |
|---|---|
| 29 May 2025 |
8-K/A: Regulation FD Disclosure; Other Events
Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation... |
| 08 Mar 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On December 16, 2022 (the “Separation Date”), R.A. Session II, the former President and Chief Executive Officer of the Company, resigned from his operating role, effective immediately. At such time, Mr. Session remained a member of the B... |
| 06 Jan 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
As previously reported in the Original Form 8-K, the Company’s board of directors (the “Board”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022. |
| 31 Oct 2022 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste ... |
| 05 Mar 2021 | 8-K/A: Results of Operations and Financial Condition |
Loading...
